论文部分内容阅读
2012年国际卒中大会上,来自加拿大的皮质下卒中二级预防(SPS3)试验中期结果表明,不支持阿司匹林联合氯吡格雷治疗对皮质下小卒中二级预防的益处,联合抗血小板治疗被提前终止。皮质下小卒中是超过25%脑梗死的致病原因,也是导致血管性痴呆的最常见原因。SPS3试验是在8个国家进行的一项随机多中心临床试验,旨在为减少卒中复发、认知能力的下降和严重血管事件制定策略。研究采用磁共振成像(MRⅠ)确诊,受试者在180d内无颈动脉狭窄或心脏来源的严重栓塞。采用析因设计,
The 2012 Stroke Conference, Mid-Stroke Prevention Secondary Stroke Prevention (SPS3) from Canada Midterm results indicate that combined antiplatelet therapy is discontinued prematurely without the benefit of aspirin plus clopidogrel in secondary prevention of subcortical minor stroke . Subcortical minor stroke is the causative agent of more than 25% of cerebral infarctions and is also the most common cause of vascular dementia. The SPS3 trial is a randomized, multicenter clinical trial in eight countries aiming to develop strategies to reduce stroke recurrence, cognitive decline and severe vascular events. The study was diagnosed by magnetic resonance imaging (MR Ⅰ), the subjects within 180 days without carotid artery stenosis or serious embolism of the heart. Using factorial design,